☰
×
News
Top 20
Insights
Insights+
ThoughtSpot
Interviews
Viewpoints
Exclusive
Spotlight
Events
Magazine
Bespoke
Newswire
x
Search
Search here
Search here
Subscribe Now
Galderma
Galderma Reports the US FDA’s Approval of Nemluvio (Nemolizumab) for Treating Prurigo Nodularis (PN)
August 13, 2024
Galderma Reports US FDA and EMA Filing Acceptances for Nemolizumab to Treat Prurigo Nodularis and Atopic Dermatitis; US FDA grants...
February 14, 2024
Galderma Receives Health Canada’s Approval for Restylane SHAYPE for Chin Augmentation
January 22, 2024
Galderma Presented P-III Trial (OLYMPIA 2) Results of Nemolizumab for the Treatment of Prurigo Nodularis at WCD 2023
July 4, 2023
Galderma Presents P-III Trial (OLYMPIA 2) of Nemolizumab for Prurigo Nodularis at AAD 2023
March 20, 2023
Galderma Reports Results of Nemolizumab in P-III (OLYMPIA 2) Trial for the Treatment of Prurigo Nodularis
June 22, 2022
Load more...
Back to Home
Modal title
×
Modal body text goes here.